Fusion and Niowave ink $5M collaboration

By AuntMinnie.com staff writers

June 14, 2022 -- McMaster University spin-off company Fusion Pharmaceuticals and superconducting accelerator technology firm Niowave have inked a $5 million supply agreement for the development, production, and supply of actinium-225.

The cash will support Niowave's efforts to increase its production of actinium-225. As part of the deal, Fusion will have guaranteed access to a predetermined percentage of the radiopharmaceutical as well as preferred access to any excess supply.

Fusion is developing actinium-based targeted alpha therapy. Actinium-225 decay kills tumor cell DNA, it said. The company already has existing agreements with Canadian particle accelerator center TRIUMF and the U.S. Department of Energy.

Copyright © 2022 AuntMinnie.com

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a AuntMinnie.com password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking